Lumexa Imaging Holdings, Inc. reported record advanced-modality imaging volumes and $23.1 million in free cash flow for the second quarter [1].
The results signal a period of growth for the medical imaging provider as it expands its high-tech diagnostic capabilities and enters strategic partnerships.
The company said these figures during a virtual conference call on Aug. 19, covering the fiscal quarter that ended June 30, 2026 [2, 5]. Along with the record volumes, the company highlighted significant growth in positron emission tomography (PET), and other advanced-modality services [3, 4].
Lumexa provided updated financial guidance for the full year of 2026. The company expects adjusted EBITDA to fall between $235 million and $241 million [3]. Total revenue for the year is projected to reach between $1.05 billion and $1.10 billion [6].
Earnings-per-share guidance for the full year is currently estimated between 71 cents and 77 cents per share [6]. These projections come as the company integrates a new joint venture with the Hospital for Special Surgery [3].
Management focused on the expansion of its diagnostic footprint during the call. The company aims to leverage its current momentum in advanced imaging to secure a larger share of the specialized diagnostics market—a move supported by its current cash flow position [1, 4].
“Lumexa Imaging reported record advanced-modality imaging volumes.”
The combination of record imaging volumes and a strategic partnership with a prestigious institution like the Hospital for Special Surgery suggests Lumexa is pivoting toward higher-margin, specialized diagnostics. By targeting advanced modalities like PET, the company is positioning itself to capture more complex medical cases, which typically command higher reimbursement rates than standard imaging.
